FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169238766> ?p ?o ?g. }

• W2169238766 endingPage "29" @default.
• W2169238766 startingPage "22" @default.
• W2169238766 abstract "The expression of alpha(v)beta(3) and glucose metabolism are upregulated in many malignant lesions, and both are known to correlate with an aggressive phenotype. We evaluated whether assessment of alpha(v)beta(3) expression and of glucose metabolism with PET using (18)F-galacto-RGD and (18)F-FDG provides complementary information in cancer patients.Eighteen patients with primary or metastatic cancer (non-small cell lung cancer [NSCLC], n = 10; renal cell carcinoma, n = 2; rectal cancer, n = 2; others, n = 4) were examined with PET using (18)F-galacto-RGD and (18)F-FDG. Standardized uptake values (SUVs) were derived by volume-of-interest analysis. (18)F-Galacto-RGD and (18)F-FDG PET results were compared using linear regression analysis for all lesions (n = 59; NSCLC, n = 39) and for primaries (n = 14) and metastases to bone (n = 11), liver (n = 10), and other organs (n = 24) separately.The sensitivity of (18)F-galacto-RGD PET compared with clinical staging was 76%. SUVs for (18)F-FDG ranged from 1.3 to 23.2 (mean +/- SD, 7.6 +/- 4.9) and were significantly higher than SUVs for (18)F-galacto-RGD (range, 0.3-6.8; mean +/- SD, 2.7 +/- 1.5; P < 0.001). There was no significant correlation between the SUVs for (18)F-FDG and (18)F-galacto-RGD for all lesions (r = 0.157; P = 0.235) or for primaries, osseous or soft-tissue metastases separately (P > 0.05). For the subgroup of lesions in NSCLC, there was a weak correlation between (18)F-FDG and (18)F-galacto-RGD uptake (r = 0.353; P = 0.028).Tracer uptake of (18)F-galacto-RGD and (18)F-FDG does not correlate closely in malignant lesions. Whereas (18)F-FDG PET is more sensitive for tumor staging, (18)F-galacto-RGD PET warrants further evaluation for planning and response evaluation of targeted molecular therapies with antiangiogenic or alpha(v)beta(3)-targeted drugs." @default.
• W2169238766 created "2016-06-24" @default.
• W2169238766 creator A5000481071 @default.
• W2169238766 creator A5000610387 @default.
• W2169238766 creator A5006830341 @default.
• W2169238766 creator A5031933240 @default.
• W2169238766 creator A5050136275 @default.
• W2169238766 creator A5051959238 @default.
• W2169238766 creator A5060810694 @default.
• W2169238766 creator A5061450233 @default.
• W2169238766 creator A5066200247 @default.
• W2169238766 date "2007-12-12" @default.
• W2169238766 modified "2023-10-13" @default.
• W2169238766 title "Comparison of Integrin α_vβ₃ Expression and Glucose Metabolism in Primary and Metastatic Lesions in Cancer Patients: A PET Study Using ¹⁸F-Galacto-RGD and ¹⁸F-FDG" @default.
• W2169238766 cites W154441448 @default.
• W2169238766 cites W1734622341 @default.
• W2169238766 cites W1973951040 @default.
• W2169238766 cites W1979712189 @default.
• W2169238766 cites W1984752350 @default.
• W2169238766 cites W1996489028 @default.
• W2169238766 cites W2004182520 @default.
• W2169238766 cites W2011217812 @default.
• W2169238766 cites W2012437716 @default.
• W2169238766 cites W2013346504 @default.
• W2169238766 cites W2020940298 @default.
• W2169238766 cites W2024846013 @default.
• W2169238766 cites W2032338421 @default.
• W2169238766 cites W2041618472 @default.
• W2169238766 cites W2046445272 @default.
• W2169238766 cites W2064737157 @default.
• W2169238766 cites W2079892729 @default.
• W2169238766 cites W2085330774 @default.
• W2169238766 cites W2115068140 @default.
• W2169238766 cites W2120172300 @default.
• W2169238766 cites W2120220319 @default.
• W2169238766 cites W2138723251 @default.
• W2169238766 cites W2143444429 @default.
• W2169238766 cites W2150818243 @default.
• W2169238766 cites W2153988810 @default.
• W2169238766 cites W2155797861 @default.
• W2169238766 cites W2169234727 @default.
• W2169238766 cites W2319736817 @default.
• W2169238766 cites W4230926334 @default.
• W2169238766 doi "https://doi.org/10.2967/jnumed.107.045864" @default.
• W2169238766 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18077538" @default.
• W2169238766 hasPublicationYear "2007" @default.
• W2169238766 type Work @default.
• W2169238766 sameAs 2169238766 @default.
• W2169238766 citedByCount "157" @default.
• W2169238766 countsByYear W21692387662012 @default.
• W2169238766 countsByYear W21692387662013 @default.
• W2169238766 countsByYear W21692387662014 @default.
• W2169238766 countsByYear W21692387662015 @default.
• W2169238766 countsByYear W21692387662016 @default.
• W2169238766 countsByYear W21692387662017 @default.
• W2169238766 countsByYear W21692387662018 @default.
• W2169238766 countsByYear W21692387662019 @default.
• W2169238766 countsByYear W21692387662020 @default.
• W2169238766 countsByYear W21692387662021 @default.
• W2169238766 countsByYear W21692387662022 @default.
• W2169238766 countsByYear W21692387662023 @default.
• W2169238766 crossrefType "journal-article" @default.
• W2169238766 hasAuthorship W2169238766A5000481071 @default.
• W2169238766 hasAuthorship W2169238766A5000610387 @default.
• W2169238766 hasAuthorship W2169238766A5006830341 @default.
• W2169238766 hasAuthorship W2169238766A5031933240 @default.
• W2169238766 hasAuthorship W2169238766A5050136275 @default.
• W2169238766 hasAuthorship W2169238766A5051959238 @default.
• W2169238766 hasAuthorship W2169238766A5060810694 @default.
• W2169238766 hasAuthorship W2169238766A5061450233 @default.
• W2169238766 hasAuthorship W2169238766A5066200247 @default.
• W2169238766 hasBestOaLocation W21692387661 @default.
• W2169238766 hasConcept C121608353 @default.
• W2169238766 hasConcept C126322002 @default.
• W2169238766 hasConcept C142724271 @default.
• W2169238766 hasConcept C2776256026 @default.
• W2169238766 hasConcept C2777472916 @default.
• W2169238766 hasConcept C2779013556 @default.
• W2169238766 hasConcept C2989005 @default.
• W2169238766 hasConcept C526805850 @default.
• W2169238766 hasConcept C71924100 @default.
• W2169238766 hasConceptScore W2169238766C121608353 @default.
• W2169238766 hasConceptScore W2169238766C126322002 @default.
• W2169238766 hasConceptScore W2169238766C142724271 @default.
• W2169238766 hasConceptScore W2169238766C2776256026 @default.
• W2169238766 hasConceptScore W2169238766C2777472916 @default.
• W2169238766 hasConceptScore W2169238766C2779013556 @default.
• W2169238766 hasConceptScore W2169238766C2989005 @default.
• W2169238766 hasConceptScore W2169238766C526805850 @default.
• W2169238766 hasConceptScore W2169238766C71924100 @default.
• W2169238766 hasIssue "1" @default.
• W2169238766 hasLocation W21692387661 @default.
• W2169238766 hasLocation W21692387662 @default.
• W2169238766 hasOpenAccess W2169238766 @default.
• W2169238766 hasPrimaryLocation W21692387661 @default.
• W2169238766 hasRelatedWork W2064573700 @default.
• W2169238766 hasRelatedWork W2172237894 @default.
• W2169238766 hasRelatedWork W2370262613 @default.

• next